Long-term Follow-up Study of BRL-101 for TDT
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
- EligibilityCriteria: Inclusion Criteria:  Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s) Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.  Exclusion Criteria:  - There are no exclusion criteria for this study - HealthyVolunteers: No - Gender: All - MinimumAge: 3 Years - MaximumAge: 35 Years - StdAgeList: Child, Adult - StudyPopulation: Subjects with transfusion-dependent β-thalassemia who have been treated with BRL-101. - SamplingMethod: Non-Probability Sample